Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

A network of molecules and atoms of glass and crystals constitute a single system. 3D illustration

Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.

Alcohol-involved injuries linked to increased risk of dying in the next year

Previous article

A-HIPI decision model can predict survival in adults with advanced-stage Hodgkin lymphoma

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News